## Why Omeprazole is right Omeprazole is a proton pump inhibitor (PPI) that directly targets the structure marked **A** — the H+/K+ ATPase on the apical/canalicular membrane of the parietal cell. As a prodrug, omeprazole requires activation in the acidic environment of the canaliculus, where it forms the active sulfenamide that irreversibly binds to cysteine residues on the pump. This irreversible inhibition lasts for the lifetime of the pump (~24–36 hours), making PPIs the most potent acid suppressors available. They are superior to H2-receptor antagonists because they block the final common pathway rather than just one upstream signaling route (Guyton & Hall 14e Ch 65; KD Tripathi 9e Ch 47). ## Why each distractor is wrong - **Ranitidine**: While H2-receptor antagonists do reduce acid secretion, they only block the histamine pathway (receptor **B**). Since the H+/K+ ATPase (**A**) can still be activated by gastrin and acetylcholine via alternative pathways, H2 blockers are less potent than PPIs and allow breakthrough acid secretion — explaining this patient's treatment failure. - **Sucralfate**: This is a mucosal protectant that forms a barrier over the ulcer but does not inhibit the H+/K+ ATPase (**A**) or reduce acid secretion. It is used as adjunctive therapy, not as primary acid suppression. - **Bismuth subsalicylate**: While effective against H. pylori, this agent does not directly inhibit the H+/K+ ATPase (**A**). Its role is antimicrobial, not direct pump inhibition. It is used in triple/quadruple therapy for H. pylori eradication, not as monotherapy for acid suppression. **High-Yield:** PPIs are prodrugs requiring acidic activation in the canaliculus — they must be taken 30–60 minutes before breakfast when the stomach is acidic and pumps are maximally inserted into the membrane. [cite: Guyton & Hall 14e Ch 65; KD Tripathi 9e Ch 47]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.